Navigation Links
Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board
Date:8/26/2014

Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School and was selected and served as the Chief Medical Resident at M.G.H. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology. Roger was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School.

About NVR-1221

NVR-1221 is a small molecule, direct-acting antiviral, for oral administration in patients with Chronic Hepatitis B (CHB) that inhibits the HBV core or capsid protein. HBV core is a novel and promising drug target with multiple activities required for viral replication and persistence. Inhibition of HBV core protein function by NVR-1221 offers the potential for a more efficient suppression of the virus leading to improved durable viral suppression and functional cure rates.

NVR-1221 is in Phase 1a clinical studies in New Zealand following successful completion of the Clinical Trial Application (CTA) regulatory process. The Phase 1a clinical study will investigate the dose-related safety/tolerance and pharmacokinetics (PK) of NVR-1221 in approximately 40 healthy volunteers. Upon completion and satisfactory outcome of the Phase 1a clinical study, Novira will commence a Phase 1b clinical study to test the safety, PK and initial antiviral activity of NVR-1221 in patients with chronic HBV infection.

About HBV

Hepatitis B infection presents a significant unmet medical need with an estimated 350 million people worldwide living with chronic HBV infecti
'/>"/>

SOURCE Novira Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
2. MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer
3. Asterias Biotherapeutics Announces Investor Briefing Conference Call and Webcast
4. Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day
5. Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer
6. Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution
7. PTC Therapeutics to Participate at Upcoming Investor Conferences
8. Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
9. Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update
10. Aratana Therapeutics Reports Second Quarter 2014 Results
11. Mirati Therapeutics Receives Orphan Designation from U.S. Food & Drug Administration for Mocetinostat in Diffuse Large B-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014  Actavis plc (NYSE: ... has received a complete response letter from the ... New Drug Application (NDA) for the fixed-dose combination ... of hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... in the receipt of a complete response letter, ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , PHILADELPHIA, June 19 Kensey Nash Corporation (Nasdaq: ... and President, received the Ernst & Young Entrepreneur Of The ... in the greater Philadelphia region. According to Ernst & ... and leading dynamic, growing businesses. Joe Kaufmann was selected ...
... cases of E. coli infection in 28 states ... are warning consumers not to eat any Nestlé Toll House ... E. coli contamination. , In response to the Food ... was voluntarily recalling its Toll House refrigerated cookie dough items. ...
... ... which provides an invaluable service to many patients who need blood products. , ... Washington (Vocus) June 19, 2009 -- Children,s ... which provides an invaluable service to many patients who need blood products. Children,s National is ...
... levels in patients , FRIDAY, June 19 (HealthDay News) ... may explain brain gray matter reductions experienced by patients ... found an association between fibromyalgia and reductions in gray ... , In this new study, Dr. Patrick B. Wood, ...
... ARDEE, Ireland, June 19 Warner Chilcott Limited (Nasdaq: ... Wachovia,s 19th Annual Mid-Year Equity Conference on Wednesday, June 24, ... will be Rochelle Fuhrmann, Senior Director, Investor Relations. , ... interested parties at www.wcrx.com under the Investor Relations ...
... ... Control Spread of Infectious Diseases , ... Fargo, ND (PRWEB) June 19, 2009 - Last week, the World Health Organization declared ... state health officials in the U.S. are urging healthcare providers to take precautions to limit ...
Cached Medicine News:Health News:Kensey Nash Corporation's CEO & President, Joe Kaufmann Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Greater Philadelphia Region 2Health News:Kensey Nash Corporation's CEO & President, Joe Kaufmann Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Greater Philadelphia Region 3Health News:Nestlé Recalls Cookie Dough Products 2Health News:Children's National Medical Center Dedicates New Blood Donor Center 2Health News:Children's National Medical Center Dedicates New Blood Donor Center 3Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 2Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 3Health News:Real-Time Locating Technology Helps Contain Pandemic Outbreaks 4
... Avaulta™ BioSynthetic Mesh ... mesh coated in the ... absorbable, hydrophilic film of ... segments of the Avaulta™ ...
The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
... Pelvicol® Acellular Collagen Matrix delivers the ... exceptional strength, versatility, and durability in ... the effectiveness of site-specific defect repair ... sterile, biocompatible, crosslinked porcine dermal collagen ...
... The QIAamp Viral RNA ... viral nucleic acids from cell-free ... nucleic acids that can be ... but are not limited to, ...
Medicine Products: